☆ 4.7 Meeting Abstract

Entinostat in combination with nivolumab for patients with advanced cholangiocarcinoma and pancreatic adenocarcinoma.

JOURNAL OF CLINICAL ONCOLOGY (2018)

Journal

JOURNAL OF CLINICAL ONCOLOGY

Volume 36, Issue 15, Pages -

Publisher

AMER SOC CLINICAL ONCOLOGY

DOI: 10.1200/JCO.2018.36.15_suppl.TPS4151

Keywords

-

Categories

Oncology

Ask authors/readers for more resources

Protocol

Community support

Reagent

Community support

Authors

I am an author on this paper

Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7

Not enough ratings

Secondary Ratings

Novelty

-

Significance

-

Scientific rigor

-

Rate this paper

Recommended

Article Oncology

Negative prognostic implications of splenomegaly in nivolumab-treated advanced or recurrent pancreatic adenocarcinoma

Shih-Hung Yang, Li-Chun Lu, Hsiang-Fong Kao, Bang-Bin Chen, Ting-Chun Kuo, Sung-Hsin Kuo, Yu-Wen Tien, Li-Yuan Bai, Ann-Lii Cheng, Kun-Huei Yeh

Summary: The study found that in patients with advanced or recurrent PDAC receiving nivolumab-based therapy, those with a spleen volume of ≥267 mL had significantly lower overall survival, while those with a spleen volume of <267 mL, ≤2 lines of prior chemotherapy, ECOG performance status of 0-2, add-on nivolumab with stable disease after prior therapy, concomitant or sequential cell therapy, high lymphocyte count, and total bilirubin <1 mg/dL were independent favorable prognostic factors for overall survival.

ONCOIMMUNOLOGY (2021)

Add to Collection

Article Oncology

Pembrolizumab in Combination with Neoadjuvant Chemoradiotherapy for Patients with Resectable Adenocarcinoma of the Gastroesophageal Junction

Mojun Zhu, Chunhua Chen, Nathan R. Foster, Christopher Hartley, Taofic Mounajjed, Marcela A. Salomao, Briant F. Fruth, Staci E. Beamer, Yohan Kim, Susan M. Harrington, Henry C. Pitot, Cristobal T. Sanhueza, Yening Feng, Joerg Herrmann, Robert R. McWilliams, Fabrice Lucien, Bing Q. Huang, Wen Wee Ma, Tanios S. Bekaii-Saab, Haidong Dong, Dennis Wigle, Daniel H. Ahn, Chris L. Hallemeier, Shanda Blackmon, Harry H. Yoon

Summary: This study investigated the feasibility and efficacy of pembrolizumab-containing trimodality therapy in patients with gastroesophageal junction adenocarcinoma. The results showed that adding pembrolizumab was tolerable but did not meet the expected pathologic complete response rate. Patients with high PD-L1 expression were more likely to achieve tumor response.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Multidisciplinary Sciences

The PEMDAC phase 2 study of pembrolizumab and entinostat in patients with metastatic uveal melanoma

Lars Ny, Henrik Jespersen, Joakim Karlsson, Samuel Alsen, Stefan Filges, Charlotta All-Eriksson, Bengt Andersson, Ana Carneiro, Hildur Helgadottir, Max Levin, Ingrid Ljuslinder, Roger Olofsson Bagge, Vasu R. Sah, Ulrika Stierner, Anders Stahlberg, Gustav Ullenhag, Lisa M. Nilsson, Jonas A. Nilsson

Summary: The combination of HDAC inhibitor entinostat with anti-PD-1 antibody pembrolizumab shows durable responses in a subset of patients with metastatic uveal melanoma. Factors such as wildtype BAP1 gene, low tumor burden, and iris melanoma may be associated with better treatment response and longer survival.

NATURE COMMUNICATIONS (2021)

Add to Collection

Article Oncology

ILUSTRO: Phase II Multicohort Trial of Zolbetuximab in Patients with Advanced or Metastatic Claudin 18.2-Positive Gastric or Gastroesophageal Junction Adenocarcinoma

Samuel J. Klempner, Keun-Wook Lee, Kohei Shitara, Jean-Phillippe Metges, Sara Lonardi, David H. Ilson, Nicola Fazio, Tae Yong Kim, Li-Yuan Bai, Diarmuid Moran, Jianning Yang, Ahsan Arozullah, Jung Wook Park, Jeffrey J. Raizer, Yung-Jue Bang, Manish A. Shah

Summary: This study examined the efficacy and safety of zolbetuximab in combination with other drugs in CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma. The results showed that zolbetuximab plus mFOLFOX6 demonstrated promising efficacy in previously untreated patients with CLDN18.2-positive tumors. These findings support the use of zolbetuximab as a first-line treatment option.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Immunology

First-line PD-1 inhibitors combination therapy for patients with advanced cholangiocarcinoma: A retrospective real-world study

Ziqi Ye, Yanfang Zhang, Jie Chen, Xiaoting Wang, Yun Hong, Qingwei Zhao

Summary: This study assessed the impact of PD-1 inhibitors combination therapy on the survival of patients with advanced cholangiocarcinoma. The results demonstrated that this approach has promising efficacy and manageable adverse events, making it a first-line treatment for advanced cholangiocarcinoma in real-world settings.

INTERNATIONAL IMMUNOPHARMACOLOGY (2023)

Add to Collection

Article Oncology

Combination Dabrafenib and Trametinib Versus Combination Nivolumab and Ipilimumab for Patients With Advanced BRAF-Mutant Melanoma: The DREAMseq Trial-ECOG-ACRIN EA6134

Michael B. Atkins, Sandra J. Lee, Bartosz Chmielowski, Ahmad A. Tarhini, Gary I. Cohen, Thach-Giao Truong, Helen H. Moon, Diwakar Davar, Mark O'Rourke, Joseph J. Stephenson, Brendan D. Curti, Walter J. Urba, Joanna M. Brell, Pauline Funchain, Kari L. Kendra, Alexandra P. Ikeguchi, Anthony Jaslowski, Charles L. Bane, Mark A. Taylor, Madhuri Bajaj, Robert M. Conry, Robert J. Ellis, Theodore F. Logan, Noel Laudi, Jeffrey A. Sosman, David G. Crockett, Andrew L. Pecora, Ian J. Okazaki, Sowjanya Reganti, Sunandana Chandra, Samantha Guild, Helen X. Chen, Howard Z. Streicher, Jedd D. Wolchok, Antoni Ribas, John M. Kirkwood

Summary: Combination programmed cell death protein 1/cytotoxic T-cell lymphocyte-4-blockade and dual BRAF/MEK inhibition have shown significant clinical benefit in patients with BRAFV600-mutant metastatic melanoma. This study aimed to determine the best initial treatment or treatment sequence in this population.

JOURNAL OF CLINICAL ONCOLOGY (2023)

Add to Collection

Article Oncology

Combination of pembrolizumab and pelareorep promotes anti-tumour immunity in advanced pancreatic adenocarcinoma (PDAC)

Devalingam Mahalingam, Siqi Chen, Ping Xie, Houra Loghmani, Thomas Heineman, Aparna Kalyan, Sheetal Kircher, Irene B. Helenowski, Xinlei Mi, Victoria Maurer, Matt Coffey, Mary Mulcahy, Al- Benson, Bin Zhang

Summary: This study evaluates the efficacy of pelareorep and pembrolizumab in treating PDAC patients by inducing anti-tumour immunological changes. The initial results show that some patients experienced clinical benefit and there were observed changes in immunological and metabolic biomarkers.

BRITISH JOURNAL OF CANCER (2023)

Add to Collection

Article Oncology

Long Term Results and Prognostic Biomarkers for Anti-PD1 Immunotherapy Used after BRAFi/MEKi Combination in Advanced Cutaneous Melanoma Patients

Pawel Rogala, Anna M. Czarnecka, Bozena Cybulska-Stopa, Krzysztof Ostaszewski, Karolina Piejko, Marcin Zietek, Robert Dziura, Ewa Rutkowska, Lukasz Galus, Natasza Kempa-Kaminska, Joanna Seredynska, Wieslaw Bal, Katarzyna Kozak, Anna Surus-Hyla, Tomasz Kubiatowski, Grazyna Kaminska-Winciorek, Rafal Suwinski, Jacek Mackiewicz, Piotr Rutkowski

Summary: This study aimed to evaluate the association between different genotypes of human papillomavirus (HPV) and the risk of cervical cancer in Sichuan province, China.

CANCERS (2022)

Add to Collection

Article Oncology

Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients

Chirayu Mohindroo, Merve Hasanov, Jane E. Rogers, Wenli Dong, Laura R. Prakash, Seyda Baydogan, Jonathan D. Mizrahi, Michael J. Overman, Gauri R. Varadhachary, Robert A. Wolff, Milind M. Javle, David R. Fogelman, Michael T. Lotze, Michael P. Kim, Matthew H. G. Katz, Shubham Pant, Ching-Wei D. Tzeng, Florencia McAllister

Summary: The use of antibiotics may predict outcomes in patients with pancreatic ductal adenocarcinoma (PDAC). In metastatic PDAC patients, antibiotic consumption is associated with significantly longer overall survival (OS) and progression-free survival (PFS). Antibiotics-associated modulation of the microbiome is linked to improved outcomes in metastatic PDAC patients.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Nivolumab and ipilimumab in combination with radiotherapy in patients with high-risk locally advanced squamous cell carcinoma of the head and neck

Jennifer M. Johnson, Ioannis A. Vathiotis, Larry A. Harshyne, Ayesha Ali, Voichita Bar Ad, Rita Axelrod, Emily Lorber, Joseph Curry, David M. Cognetti, Adam J. Luginbuhl, Madalina Tuluc, Scott Keith, My G. Mahoney, Athanassios Argiris

Summary: This is a phase I study on the combination treatment of nivolumab and ipilimumab for squamous cell carcinoma of the head and neck. The results show that this treatment has sufficient clinical activity to support further development. Early changes in circulating biomarkers can predict treatment outcomes as well as in-field soft tissue ulceration.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2023)

Add to Collection

Article Oncology

Integrative immune transcriptomic classification improves patient selection for precision immunotherapy in advanced gastro-oesophageal adenocarcinoma

Manuel Cabeza-Segura, Valentina Gambardella, Francisco Gimeno-Valiente, Juan Antonio Carbonell-Asins, Lorena Alarcon-Molero, Arturo Gonzalez-Vilanova, Sheila Zuniga-Trejos, Pilar Rentero-Garrido, Rosana Villagrasa, Mireia Gil, Ana Dura, Paula Richart, Noelia Alonso, Marisol Huerta, Susana Rosello, Desamparados Roda, Noelia Tarazona, Carolina Martinez-Ciarpaglini, Josefa Castillo, Andres Cervantes, Tania Fleitas

Summary: This study investigates the immune microenvironment features related to sensitivity or resistance to immune checkpoint inhibitors (CPIs) in advanced gastro-oesophageal cancer (GEA). Through transcriptomic analysis, the researchers identified a cluster of tumors with high gene signatures related to immunomodulatory pathways and immunotherapy response, suggesting that these tumors may benefit the most from CPIs. The findings were validated in an external population, highlighting the potential of using transcriptomic classification to improve precision immunotherapy for GEA patients.

BRITISH JOURNAL OF CANCER (2022)

Add to Collection

Article Oncology

Circulating Protein Biomarkers for Prognostic Use in Patients with Advanced Pancreatic Ductal Adenocarcinoma Undergoing Chemotherapy

Sidsel C. Lindgaard, Emil Maag, Zsofia Sztupinszki, Inna M. Chen, Astrid Z. Johansen, Benny Jensen, Stig E. Bojesen, Dorte L. Nielsen, Zoltan Szallasi, Julia S. Johansen

Summary: This study investigated the relationship between the levels of 92 circulating proteins and survival in patients with advanced pancreatic ductal adenocarcinoma. Two protein signatures were identified that could discriminate patients with different overall survival durations, and further analysis explored early changes in protein levels and protein expression in different treatment groups.

CANCERS (2022)

Add to Collection

Article Dermatology

Updated analysis of nivolumab and ipilimumab combination therapy in Japanese patients with advanced melanoma

Akira Takahashi, Kenjiro Namikawa, Dai Ogata, Shunichi Jinnai, Eiji Nakano, Naoya Yamazaki

Summary: The efficacy and safety of nivolumab and ipilimumab combination therapy for advanced melanoma in Japanese patients were re-evaluated. The response rate was higher in patients who had not received prior systemic therapy. However, the efficacy of the combination therapy in Japanese patients appeared to be lower compared to global studies and non-Asian patients.

JOURNAL OF DERMATOLOGY (2023)

Add to Collection

Article Medicine, General & Internal

Combination of GT90001 and nivolumab in patients with advanced hepatocellular carcinoma: a multicenter, single-arm, phase 1b/2 study

Chiun Hsu, Yi-Fang Chang, Chia-Jui Yen, Yu-Wei Xu, Min Dong, You-Zhi Tong

Summary: GT90001 plus nivolumab has a manageable safety profile and promising anti-tumor activity in patients with advanced HCC. The study results show that GT90001 combined with nivolumab treatment can effectively reduce disease progression and improve patient survival.

BMC MEDICINE (2023)

Add to Collection

Article Multidisciplinary Sciences

A combination therapy of bortezomib, CXCR4 inhibitor, and checkpoint inhibitor is effective in cholangiocarcinoma in vivo

Ling Li, Yang Zhou, Yicheng Zhang, Haijie Hu, Hai-Quan Mao, Florin M. Selaru

Summary: Cholangiocarcinoma (CCA) is a biliary tree malignancy with poor prognosis. Cancer-associated fibroblasts (CAFs) in the tumor microenvironment (TME) contribute to drug resistance. This study established CCA complex patient-derived organoids (cPDOs) to assess the resistance mechanisms, and found that over-expression of CXCR4 in CAFs correlated with resistance to bortezomib. Inhibition of CXCR4 reversed the resistance and enhanced the sensitivity of CCA to bortezomib and anti-PD1 treatment, suggesting a promising triple therapy approach.

ISCIENCE (2023)

Add to Collection

Article Oncology

Estimating 12-week death probability in patients with refractory metastatic colorectal cancer: the Colon Life nomogram

F. Pietrantonio, R. Miceli, L. Rimassa, S. Lonardi, G. Aprile, A. Mennitto, F. Marmorino, S. Bozzarelli, L. Antonuzzo, E. Tamburini, F. Morano, D. Rossini, F. Battaglin, M. Baretti, R. Berenato, V. Formica, S. Mosconi, F. Petrelli, M. Ghidini, F. Loupakis, D. Spada, S. Cinieri, G. Beretta, A. Falcone, F. de Braud, C. Cremolini

ANNALS OF ONCOLOGY (2017)

Add to Collection

Article Oncology

Emergence of KRAS-mutation in liver metastases after an anti-EGFR treatment in patient with colorectal cancer: Are we aware of the therapeutic impact of intratumor heterogeneity?

M. Baretti, N. Personenia, A. Destro, A. Santoro, L. Rimassa

CANCER BIOLOGY & THERAPY (2018)

Add to Collection

Article Oncology

Effect of Comorbidities in Stage II/III Colorectal Cancer Patients Treated With Surgery and Neoadjuvant/Adjuvant Chemotherapy: A Single-Center, Observational Study

Marina Baretti, Lorenza Rimassa, Nicola Personeni, Laura Giordano, Maria Chiara Tronconi, Tiziana Pressiani, Silvia Bozzarelli, Armando Santoro

CLINICAL COLORECTAL CANCER (2018)

Add to Collection

Article Oncology

The role of epigenetic therapies in colorectal cancer

Marina Baretti, Nilofer Saba Azad

CURRENT PROBLEMS IN CANCER (2018)

Add to Collection

Review Pharmacology & Pharmacy

DNA mismatch repair in cancer

Marina Baretti, Dung T. Le

PHARMACOLOGY & THERAPEUTICS (2018)

Add to Collection

Meeting Abstract Oncology

The impact of the immune microenvironment in patients with GEP-NETs.

Marina Baretti, Qingfeng Zhu, Marianna Zahurak, Timothy M. Pawlik, Robert A. Anders, Ana De Jesus-Acosta

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Meeting Abstract Oncology

Chemoradiation-induced alteration of programmed death-ligand 1 and CD8+ tumor-infiltrating lymphocytes in rectal cancer

Marina Baretti, Wei Fu, Hao Wang, Robert A. Anders, Nilofer Saba Azad, Qingfeng Zhu

JOURNAL OF CLINICAL ONCOLOGY (2019)

Add to Collection

Article Gastroenterology & Hepatology

The Significance of Ascites in Patients With Pancreatic Ductal Adenocarcinoma A Case-Control Study

Marina Baretti, Bhargavi Pulluri, Hua-Ling Tsai, Amanda L. Blackford, Christopher L. Wolfgang, Daniel Laheru, Lei Zheng, Joseph Herman, Dung T. Le, Amol K. Narang, Ana de Jesus-Acosta

PANCREAS (2019)

Add to Collection

Article Medicine, Research & Experimental

A phase 2 trial of gemcitabine and docetaxel in patients with metastatic colorectal adenocarcinoma with methylated checkpoint with forkhead and ring finger domain promoter and/or microsatellite instability phenotype

Marina Baretti, Enusha Karunasena, Marianna Zahurak, Rosalind Walker, Yang Zhao, Thomas R. Pisanic, Tza-Huei Wang, Tim F. Greten, Austin G. Duffy, Elske Gootjes, Gerrit Meijer, Henk M. W. Verheul, Nita Ahuja, James G. Herman, Nilofer S. Azad

Summary: A Phase 2 trial of gemcitabine and docetaxel in patients with CHFR-methylated, MSI-high CRC did not show tumor responses according to RECIST criteria. The median progression-free survival was 1.79 months, and the median overall survival was 15.67 months. Despite the negative results, this study demonstrates the potential of using epigenetic biomarkers as inclusion criteria for optimizing combinatorial strategies in personalized medicine.

CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2021)

Add to Collection

Article Health Care Sciences & Services

Relationship of Hepatocellular Carcinoma Stage and Hepatic Function to Health-Related Quality of Life: A Single Center Analysis

Amol Gupta, Jane Zorzi, Won Jin Ho, Marina Baretti, Nilofer Saba Azad, Paige Griffith, Doan Dao, Amy Kim, Benjamin Philosophe, Christos Georgiades, Ihab Kamel, Richard Burkhart, Robert Liddell, Kelvin Hong, Christopher Shubert, Kelly Lafaro, Jeffrey Meyer, Robert Anders, William Burns III, Mark Yarchoan

Summary: This study examined the relationship between health-related quality of life (HRQoL) and Barcelona Clinic Liver Cancer (BCLC) stage, Child-Pugh (CP) score, and Eastern Cooperative Oncology Group (ECOG) performance status in patients with hepatocellular carcinoma (HCC). The results showed that impaired liver function was associated with reduced quality of life, while the BCLC stage had poor correlation with HRQoL. Early supportive interventions may have a positive impact on HRQoL and survival outcomes for HCC patients.

HEALTHCARE (2023)

Add to Collection

Article Oncology

Salvage Ipilimumab plus Nivolumab after Anti-PD-1/PD-L1 Therapy in Advanced Hepatocellular Carcinoma

Stephanie L. Alden, Mir Lim, Chester Kao, Daniel Shu, Amit G. Singal, Anne Noonan, Paige Griffith, Marina Baretti, Won Jin Ho, Ihab Kamel, Mark Yarchoan, David Hsiehchen

Summary: Ipilimumab plus nivolumab has shown efficacy in patients with advanced HCC who have received prior anti-PD-(L)1 therapy, suggesting its potential as a salvage treatment option.

CANCER RESEARCH COMMUNICATIONS (2023)

Add to Collection

Article Oncology

Clinical, Genomic, and Transcriptomic Data Profiling of Biliary Tract Cancer Reveals Subtype-Specific Immune Signatures

Kabir Mody, Prerna Jain, Sherif M. El-Refai, Nilofer S. Azad, Daniel J. Zabransky, Marina Baretti, Rachna T. Shroff, R. Katie Kelley, Anthony B. El-Khouiery, Adam J. Hockenberry, Denise Lau, Gregory B. Lesinski, Mark Yarchoan

Summary: The immune landscape of different subtypes of biliary tract cancers (BTCs) can help improve patient selection for immunotherapy and guide treatment strategies. The study revealed diverse genetic alterations and immune biomarkers in BTC subtypes, with gallbladder cancer and specific genetic mutations associated with the immune microenvironment.

JCO PRECISION ONCOLOGY (2022)

Add to Collection

Article Oncology

An analysis of genetic heterogeneity in untreated cancers

Johannes G. Reiter, Marina Baretti, Jeffrey M. Gerold, Alvin P. Makohon-Moore, Adil Daud, Christine A. Iacobuzio-Donahue, Nilofer S. Azad, Kenneth W. Kinzler, Martin A. Nowak, Bert Vogelstein

NATURE REVIEWS CANCER (2019)

Add to Collection

Review Oncology

Precision Cancer Trials With Immunomodulatory Agents Personalizing Histology Agnostic Approaches

Marina Baretti, Nilofer Saba Azad

CANCER JOURNAL (2019)

Add to Collection

No Data Available

© Peeref 2019-2024. All rights reserved.